Neuroprotective effects of erythropoietin on rat retinas subjected to oligemia
AUTOR(ES)
Carvalho, Litia Alves de, Fleming, Renata, Sant’Anna, Moysés, Guimarães, Roberta, Dantas, Adalmir Morterá, Morizot-Leite, Eduardo, Cavalcante, Leny A., Allodi, Silvana
FONTE
Clinics
DATA DE PUBLICAÇÃO
19/04/2018
RESUMO
OBJECTIVES: Erythropoietin may have neuroprotective potential after ischemia of the central nervous system. Here, we conducted a study to characterize the protective effects of erythropoietin on retinal ganglion cells and gliotic reactions in an experimentally induced oligemia model. METHODS: Rats were subjected to global oligemia by bilateral common carotid artery occlusion and then received either vehicle or erythropoietin via intravitreal injection after 48 h; they were euthanized one week after the injection. The densities of retinal ganglion cells and contents of glial fibrillary acidic protein (astrocytes/Müller cells) and cluster of differentiation 68 clone ED1 (microglia/macrophages), assessed by fluorescence intensity, were evaluated in frozen retinal sections by immunofluorescence and epifluorescence microscopy. RESULTS: Retinal ganglion cells were nearly undetectable one week after oligemia compared with the sham controls; however, these cells were partially preserved in erythropoietin-treated retinas. The contents of glial fibrillary acidic protein and cluster of differentiation 68 clone ED1, markers for reactive gliosis, were significantly higher in retinas after bilateral common carotid artery occlusion than those in both sham and erythropoietin-treated retinas. CONCLUSIONS: The number of partially preserved retinal ganglion cells in the erythropoietin-treated group suggests that erythropoietin exerts a neuroprotective effect on oligemic/ischemic retinas. This effect could be related to the down-modulation of glial reactivity, usually observed in hypoxic conditions, clinically observed during glaucoma or retinal artery occlusion conditions. Therefore, glial reactivity may enhance neurodegeneration in hypoxic conditions, like normal-tension glaucoma and retinal ischemia, and erythropoietin is thus a candidate to be clinically applied after the detection of decreased retinal blood flow.
Documentos Relacionados
- Beneficial effects of systemic administration of recombinant human erythropoietin in rabbits subjected to subarachnoid hemorrhage
- Acute neuroprotective synergy of erythropoietin and insulin-like growth factor I
- Effects of azathioprine on response of renal anaemia to subcutaneous recombinant human erythropoietin.
- Neuroprotective effect of ketamine/xylazine on two rat models of Parkinson's disease
- Effects of GnRH administration on ovulation and fertility in ewes subjected to estrous synchronization